Susan Pekarovics, MD
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1154350320
Payments from drug & device makers
Across 366 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- IBSA Pharma Inc.$1K
- Lilly USA, LLC$1K
- Amgen$1K
- AstraZeneca$856
- Novo Nordisk$647
- AbbVie$386
- plus $2K from 31 others
What the payments were for
- Food & beverage$7,542100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| IBSA Pharma Inc. | 70 | $1,409 |
| Lilly USA, LLC | 58 | $1,195 |
| Amgen(2 entities) | 49 | $1,042 |
| AstraZeneca | 41 | $856 |
| Novo Nordisk | 33 | $647 |
| AbbVie(2 entities) | 22 | $386 |
| Sanofi-aventis U.S. LLC | 9 | $258 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $244 |
| Bayer | 7 | $171 |
| Novartis | 5 | $129 |
| Biosense Webster, Inc. | 1 | $125 |
| Abbott | 4 | $88 |
| Mannkind Corporation | 4 | $85 |
| Zealand Pharma US, Inc. | 4 | $78 |
| Boehringer Ingelheim | 3 | $78 |
| Shire North American Group Inc | 4 | $76 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Recordati_rare_diseases_inc. | 3 | $70 |
| Astellas Pharma US Inc | 3 | $62 |
| Amryt Pharma Holdings Ltd | 2 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| Kyowa Kirin, Inc. | 2 | $44 |
| Optos, Inc. | 2 | $38 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| Upsher-smith Laboratories LLC | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Pfizer | 1 | $26 |
| EUSA Pharma (US) LLC | 1 | $22 |
| Vivus LLC | 1 | $21 |
| Merck | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $13 |
| Venclose Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,563 in reported general payments places this provider in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 111 | $147,948 |
| OzempicSemaglutide | 82 | $83,064 |
| FarxigaDapagliflozin Propanediol | 77 | $66,163 |
| EliquisApixaban | 61 | $50,858 |
| JardianceEmpagliflozin | 56 | $46,655 |
| Metformin Er GastricMetformin Hcl | 24 | $35,053 |
| RybelsusSemaglutide | 31 | $32,052 |
| TradjentaLinagliptin | 30 | $26,433 |
| TrulicityDulaglutide | 24 | $25,817 |
| MyrbetriqMirabegron | 41 | $21,458 |
| Lidocaine | 89 | $20,959 |
| ProliaDenosumab | 12 | $20,054 |
| LinzessLinaclotide | 14 | $17,784 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $15,086 |
| Repatha SureclickEvolocumab | 22 | $14,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,195 | $173,766135 claims |
| Novo NordiskOzempic, Rybelsus | $647 | $115,116113 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $856 | $81,25095 claims |
| Boehringer IngelheimJardiance, Tradjenta | $78 | $73,08786 claims |
| PfizerEliquis | $26 | $50,85861 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $21,45841 claims |
| AmgenProlia | $1,042 | $20,05412 claims |
| MerckBelsomra, Janumet | $19 | $19,60136 claims |
| AbbVieLinzess, Synthroid | $386 | $18,98132 claims |
| NovartisEntresto | $129 | $6,98517 claims |
| IBSA Pharma Inc.Tirosint | $1,409 | $4,26125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Los Angeles
- Stanley HsiaLos Angeles$19.8M
- Shlomo MelmedLos Angeles$3.3M
- Sina TebiLos Angeles$2.4M
- Anthony HeaneyLos Angeles$788K
- Christian GastelumLos Angeles$421K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.